Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
Appendix
Members of the ‘AGO Breast Committee’ in alphabetical order:
Prof. Dr. Ute-Susann Albert Krankenhaus Nordwest GmbH, Frankfurt/M.
Dr. Ingo Bauerfeind Frauenklinik im Klinikum Landshut
PD Dr. Joachim Bischoff Klinikum Dessau
Prof. Dr. Jens-Uwe Blohmer Charité, Berlin
Prof. Dr. Wilfried Budach Universitätsklinikum Düsseldorf
Prof. Dr. Peter Dall Städtisches Klinikum Lüneburg
Prof. Dr. Ingo J. Diel CGG Klinik Mannheim
Prof. Dr. Tanja Fehm Universitätsfrauenklinik Düsseldorf
PD Dr. Nikos Fersis Klinikum Bayreuth
Prof. Dr. Michael Friedrich Helios-Klinikum Krefeld
Prof. Dr. Bernd Gerber Universitäts-Frauenklinik Rostock
Prof. Dr. Volker Hanf Klinikum Fürth
Prof. Dr. Nadia Harbeck Breast Center, Dept. OB&GYN, University of Munich
Prof. Dr. Jens Huober Universitätsklinikum Ulm
Prof. Dr. Christian Jackisch Klinikum Offenbach
Prof. Dr. Wolfgang Janni Universitätsklinikum Ulm
Prof. Dr. Hans H. Kreipe Medizinische Hochschule Hannover
Prof. Dr. Thorsten Kühn Klinikum Esslingen
PD Dr. Sherko Kümmel Evang. Huyssens-Stiftung, Essen
PD Dr. Cornelia Liedtke Universitätsklinikum Schleswig-Holstein, Lübeck
Prof. Dr. Sibylle Loibl GBG Forschungs GmbH, Neu-Isenburg
Prof. Dr. Hans-Joachim Lück Gynäkologisch-Onkologische Praxis Hannover
Prof. Dr. Michael P. Lux Universitätsfrauenklinik Erlangen
Prof. Dr. Nicolai Maass Universitätsklinikum Schleswig-Holstein, Kiel
Prof. Dr. Gunter von Minckwitz GBG Forschungs GmbH, Neu-Isenburg
Prof. Dr. Volker Möbus Städt. Kliniken Frankfurt-Höchst
Prof. Dr. Volkmar Müller Universitätsklinikum Hamburg-Eppendorf
Prof. Dr. Christoph Mundhenke Universitätsklinikum Schleswig-Holstein, Kiel
Prof. Dr. Ulrike Nitz Bethesda Krankenhaus Mönchengladbach
Dr. Mahdi Rezai Luisenkrankenhaus, Düsseldorf
Prof. Dr. Achim Rody Universitätsklinikum Schleswig-Holstein, Lübeck
Prof. Dr. Anton Scharl Klinikum St. Marien, Amberg
Prof. Dr. Marcus Schmidt Universitätsfrauenklinik Mainz
Prof. Dr. Rita Schmutzler Klinikum der Universität zu Köln
Prof. Dr. Andreas Schneeweiss Gynäkologische Onkologie, Heidelberg
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
Prof. Dr. Ingrid Schreer Hamburg
Prof. Dr. Florian Schütz Klinikum der Ruprecht-Karl-Univ. Heidelberg
Prof. Dr. H. Peter Sinn Klinikum der Ruprecht-Karl-Univ. Heidelberg
Prof. Dr. Erich Solomayer Universitätsklinikum des Saarlandes, Homburg
Prof. Dr. Elmar Stickeler Universitätsklinikum Aachen
PD Dr. Marc Thill Agaplesion Markus KrankenhausFrankfurt/M.
Prof. Dr. Christoph Thomssen Universitätsklinik u. Poliklinik für Gynäkologie, Halle/Saale
Prof. Dr. Michael Untch Frauenklinik / interdisziplinäres Brustzentrum Helios-Kliniken Berlin
Prof. Dr. Frederik Wenz Universitätsklinikum Mannheim
PD Dr. Isabell Witzel Brustzentrum Universitätsklinik Hamburg-Eppendorf
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
Supplemental Figures
Supplemental Figure 1. Recommendations regarding prognostic factors
Supplemental Figure 2. Subtype-specific general systemic strategies
Supplemental Figure 3. Recommendation regarding axillary staging before or after NACT
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
Supplemental Figure 4. Adjuvant Chemotherapy without concurrent Trastuzumab
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
References 1 Oxford CEBM: Level of evidence, LoE, www.cebm.net.
2 Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2016, www.ago-online.de.
3 van Gemert WA, Lanting CI, Goldbohm RA, et al. The proportion of postmenopausal breast
cancer cases in the Netherlands attributable to lifestyle-related risk factors. Breast Cancer Res
Treat. 2015;152:155-162.
4 Bao PP, Zhao GM, Shu XO, et al., Modifiable Lifestyle Factors and Triple-negative Breast Cancer
Survival: A Population-based Prospective Study. Epidemiology. 201;26:909-916.
5 http://www.konsortium-familiaerer-brustkrebs.de/fileadmin/downloads/FB-
erbliche_Belastung_V2014-09-02.pdf
6 Couch FJ, Hart SN, Sharma P et al., Inherited mutations in 17 breast cancer susceptibility genes
among a large triple-negative breast cancer cohort unselected for family history of breast
cancer. J Clin Oncol 2015;33:304–311
7 Gaudet MM, Kuchenbaecker KB, Vijai J Identification of a brca2-specific modifier locus at 6p24
related to breast cancer risk. PLoS genetics 2013;9:e1003173;Couch FJ, Wang X, McGuffog L,
Genome-wide association study in brca1 mutation carriers identifies novel loci associated with
breast and ovarian cancer risk. PLoS genetics 2013;9:e1003212
8 Antoniou AC, Casadei S, Heikkinen T, Breast-cancer risk in families with mutations in palb2. The
New England journal of medicine 2014;371:497–506
9 Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS et al Breast Cancer Screening for
women at average risk. 2015 Guideline Update from the American Cancer Society. JAMA
2015;314:1599–1614
10 Skaane P, Bandos AI, Gullien R, et al.: Comparison of digital mammography alone and digital
mammography plus tomosynthesis in a population –based screening program. Radiology
2013;267(1) 47-56
11 Skaane P, Bandos AI, Eben EB, Jebsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M,
Hofwind S, Gullien R Two-view breast tomosynthesis screening with synthetically
reconstructed projection images; Comparison with digital breast tomosynthesis with full-field
digital mammographic images. Radiology 2014:271(3)655-663
12 Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, Tuttobene P, Bricolo P,
Fanto C, Valentini M, Montemezzi S, Houssami N Incremental effect from integrating 3D-
mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection
evident for screening centres in a population-based trial. The Breast 2014;23:76-80
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
13 Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit
DS,Carlson KL, Cink TM, Barke DO, Greer LN, Miller DP, Conant EF Breast cancer screening
using tomosynthesis in combination with digital mammography. JAMA 2014;311(24):2499-
2507
14 Gilber FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY,
Purushothaman H, Strudley C, Astley SM, Morrish O, Young KC, Duffy SW. The TOMMY trial: a
comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening
Programme - a multicentre retrospective reading study comparing the diagnostic performance
of digital breast tomosynthesis and digital mammography with digital mammography alone.
Health Technol Assess. 2015 Jan;19(4):1-136. doi: 10.3310/hta19040
15 Gartlehner G, Thaler K, Chapman A, Kaminski-Hartenthaler A, Berzaczy D, Van Noord MG,
Helbich TH. Mammography in combination with breast ultrasonography versus mammography
for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 2013 Apr
30;4:CD009632. doi: 10.1002/14651858.CD009632.
16 Taglliafico A, Astengo D, Cavagnetto F, Rosasco R, Rescinito G, Monetti F, Calabrese M One-to-
one comparison between digital spot compression view and digital breast tomosynthesis. Eur
Radiol 2012;22:539-544
17 Zuley ML, Bandos AI, Ganott MA, Sumkin JH, Kelly AE, Catullo VJ, Rathfon GY, Lu AH, Gur D
Digital breast tomosynthesis versus supplemental diagnostic mammographic views for
evaluation of noncalcified breast lesions Radiology 2013;266(1):89
18 Wojcinski S, Gyapong S, Farrokh A, Soergel P, Hillemanns P, Degenhardt F. Diagnostic
performance and inter-observer concordance in lesion detection with the automated breast
volume scanner (ABVS). BMC Med Imaging. 2013 Nov 12;13:36. doi: 10.1186/1471-2342-13-
36.
19 Glatt M, Franz D, Harcos A, Junkermann H, Rauch G, Scharf A, Schuetz F, Sohn C, Heil J.
Interobserver reliability of automated breast volume scanner (ABVS) interpretation and
agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and
pathology results. Eur J Radiol. 2013 Aug;82(8):e332-6. doi: 10.1016/j.ejrad.2013.03.005. Epub
2013 Mar 27.
20 Golatta M, Baggs C, Schweitzer-Martin M, Domschke C, Schott S, Harcos A, Scharf A,
Junkermann H, Rauch G, Rom J, Sohn C, Heil J. Evaluation of an automated breast 3D-
ultrasound system by comparing it with hand-held ultrasound (HHUS) and mammography.
Arch Gynecol Obstet. 2014 Oct 14.
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
21 Choi WJ, Cha JH, Kim HH, Shin HJ, Kim H, Chae EY, Hong MJ. Comparison of automated breast
volume scanning and hand- held ultrasound in the detection of breast cancer: an analysis of
5,566 patient evaluations. Asian Pac J Cancer Prev. 2014;15(21):9101-5.
22 Skaane P, Gullien R, Eben EB, Sandhaug M, Schulz-Wendtland R, Stoeblen F.Interpretation of
automated breast ultrasound (ABUS) with and without knowledge of mammography: a reader
performance study. Acta Radiol. 2014 Mar 28. pii: 0284185114528835. [Epub ahead of print
23 Berg WA, Cosgrove DO, Doré CJ, Schäfer FK, Svensson WE, Hooley RJ, Ohlinger R, Mendelson
EB, Balu-Maestro C, Locatelli M, Tourasse C, Cavanaugh BC, Juhan V, Stavros AT, Tardivon A,
Gay J, Henry JP, Cohen-Bacrie C; BE1 Investigators. Shear-wave elastography improves the
specificity of breast US: the BE1 multinational study of 939 masses. Radiology. 2012
Feb;262(2):435-49.
24 Li G, Li DW, Fang YX, Song YJ, Deng ZJ, Gao J, Xie Y, Yin TS, Ying L, Tang KF. Performance of
shear wave elastography for differentiation of benign and malignant solid breast masses. PLoS
One. 2013 Oct 18;8(10):e76322.
25 Mann RM The effectiveness of MRI imaging in the assessment of invasive lobular carcinoma of
the breast. Magn Reson Imaging Clin N Am 2010; 18: 259-276
26 Mann RM, Loo CE, Wobbes T et al The impact of preoperative MRI on the re-excision rate in
invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2010; 119: 415-422
27 Houssami N, Turner R, Macaskill P, Turnbull LW, McCready DR, Tuttle TM, Vapiwala N, Solin L J
An individual person data meta-analysis of preoperative magnetic resonance imaging and
breast cancer recurrence. J Clin Oncol 2014;32(5):392-401
28 Evans A, Rauchhaus P, Whelehan P, Thomson K, Purdie CA, Jordan LB, Michie CO, Thompson A,
Vinnicombe S. Does shear wave ultrasound independently predict axillary lymph node
metastasis in women with invasive breast cancer? Breast Cancer Res Treat. 2013 Dec 4. [Epub
ahead of print]
29 Diepstraten SC, Sever AR, Buckens CFM, Veldhuis WB, van Dahlen T, van den Bosch MAAJ, Mali
WPTM, Verkooijen HM Value of preoperative ultrasound guided lymphnode biopsy for
preventing completion axillary lymphnode dissection in breast cancer: a systematic review and
meta-analysis. Ann Surg Oncol 2014;21:51-59
30 Gloyeske NC, Dabbs DJ, Bhargava R(): Low ER+ breast cancer: is this a distinct group? Am J Clin
Pathol 2014;141:697–701
31 Iwamoto T, Booser D, Valero V, et al.: Estrogen Receptor (ER) mRNA and ER-Related Gene
Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J
ClinOncol 2012:30;729–734.
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
32 Sanford RA, Song J, Gutierrez-Barrera AM et al., High incidence of germline BRCA mutation in
patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer.
2015;1;121:3422-3427
33 Deyarmin B et al. Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular
Subtype. Ann Surg Oncol 2013;20:87–93.
34 Yi M1, Huo L, Koenig KB, et al., Which threshold for ER positivity? a retrospective study based
on 9639 patients. Ann Oncol. 2014;25:1004-1011
35 Perry N, Broeders M, de Wolf C, et al., European guidelines for quality assurance in breast
cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2008;19:614-
622
36 Calhoun BC, Collins LC: Recommendations for excision following core needle biopsy of the
breast: A contemporary evaluation of the literature. Histopathology 2016;68:138–151
37 Menes TS, Rosenberg R, Balch S, Jaffer S, Kerlikowske K, Miglioretti DL: Upgrade of high-risk
breast lesions detected on mammography in the breast cancer surveillance consortium. Am J
Surg 2014;207:24–31
38 Dialani V, Venkataraman S, Frieling G, Schnitt SJ, Mehta TS: Does isolated flat epithelial atypia
on vacuum-assisted breast core biopsy require surgical excision? Breast J 2014;20:606–614
39 Calhoun BC, Sobel A, White RL, Gromet M, Flippo T, Sarantou T, Livasy CA: Management of flat
epithelial atypia on breast core biopsy may be individualized based on correlation with imaging
studies. Mod Pathol 2015;28:670–676
40 Yu CC, Ueng SH, Cheung YC, Shen SC, Kuo WL, Tsai HP, Lo YF, Chen SC: Predictors of
underestimation of malignancy after image-guided core needle biopsy diagnosis of flat
epithelial atypia or atypical ductal hyperplasia. Breast J 2015;21:224–232
41 Uzoaru I, Morgan BR, Liu ZG, Bellafiore FJ, Gaudier FS, Lo JV, Pakzad K: Flat epithelial atypia
with and without atypical ductal hyperplasia: To re-excise or not. Results of a 5-year
prospective study. Virchows Arch 2012;461:419–423.
42 Lewis JT, Hartmann LC, Vierkant RA, Maloney SD, Shane Pankratz V, Allers TM, Frost MH,
Visscher DW: An analysis of breast cancer risk in women with single, multiple, and atypical
papilloma. Am J Surg Pathol 2006;30:665–672
43 Wyss P, Varga Z, Rossle M, Rageth CJ: Papillary lesions of the breast: Outcomes of 156 patients
managed without excisional biopsy. Breast J 2014;20:394–401
44 Swapp RE, Glazebrook KN, Jones KN, Brandts HM, Reynolds C, Visscher DW, Hieken TJ:
Management of benign intraductal solitary papilloma diagnosed on core needle biopsy. Ann
Surg Oncol 2013;20:1900–1905
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
45 Sinn HP, Elsawaf Z, Helmchen B, Aulmann S: Early breast cancer precursor lesions: Lessons
learned from molecular and clinical studies. Breast Care (Basel) 2010;5:218–226
46 Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH: Lobular in-situ neoplasia on breast
core needle biopsy: Imaging indication and pathologic extent can identify which patients
require excisional biopsy. Ann Surg Oncol 2012;19:914–921
47 Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E: Classic lobular carcinoma
in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: Outcomes of
prospective excision. Cancer 2013;119:1073–1079
48 D'Alfonso TM, Wang K, Chiu YL, Shin SJ: Pathologic upgrade rates on subsequent excision when
lobular carcinoma in situ is the primary diagnosis in the needle core biopsy with special
attention to the radiographic target. Arch Pathol Lab Med 2013;137:927–935
49 Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ: Pleomorphic lobular carcinoma in situ
(plcis) on breast core needle biopsies: Clinical significance and immunoprofile. Am J Surg
Pathol 2008;32:1721–1726
50 Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, Schnitt SJ, Waldman FM, Chen YY: Florid
lobular carcinoma in situ: Molecular profiling and comparison to classic lobular carcinoma in
situ and pleomorphic lobular carcinoma in situ. Hum Pathol 2013;44:1998–2009
51 Ross DS, Hoda SA: Microinvasive (t1mic) lobular carcinoma of the breast: Clinicopathologic
profile of 16 cases. Am J Surg Pathol 2011;35:750–756
52 Bratthauer GL, Tavassoli FA: Lobular intraepithelial neoplasia: Previously unexplored aspects
assessed in 775 cases and their clinical implications. Virchows Arch 2002;440:134–138
53 Matrai C, D'Alfonso TM, Pharmer L, Drotman MB, Simmons RM, Shin SJ: Advocating
nonsurgical management of patients with small, incidental radial scars at the time of needle
core biopsy: A study of 77 cases. Arch Pathol Lab Med 2015;139:1137–1142
54 Miller CL, West JA, Bettini AC, Koerner FC, Gudewicz TM, Freer PE, Coopey SB, Gadd MA,
Hughes KS, Smith BL, Rafferty E, Specht MC: Surgical excision of radial scars diagnosed by core
biopsy may help predict future risk of breast cancer. Breast Cancer Res Treat 2014;145:331–
338
55 Conlon N, D'Arcy C, Kaplan JB, Bowser ZL, Cordero A, Brogi E, Corben AD: Radial scar at image-
guided needle biopsy: Is excision necessary? Am J Surg Pathol 2015;39:779–785
56 Hahn M, Krainick-Strobel U, Töllner T, Gissler J, Kluge S, Krapfl E, Peisker U, Duda V,
Degenhardt F, Sinn H, Wallwiener D, Gruber I: Interdisciplinary consensus recommendations
for the use of vacuum-assisted breast biopsy under sonographic guidance. Ultraschall in der
Medizin / European Journal of Ultrasound 2012;33:366–371
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
57 Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality after a Diagnosis of
Ductal Carcinoma in Situ. JAMA Oncol 2015;1888–96
58 Goodwin A, Parker S, Ghersi D, Wicken N. Post-operative radiotherapy for ductal carcinoma in
situ oft he breast. Cochrana Database Syst Rev 2013;11:CD000563
59 Subhedar P, Olese C, Pahil S, Morrow M, Van Zee KJ. Decreasing Recurrence Rates for Ductal
Carcinoma in Situ: Analysis of 2996 Women Treated with Breast Conserving Surgery over 30
Years. Ann Surg Oncol 2015;22:3273–3281
60 Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane
systematic review and metaanalysis. The Breast 2014;23:546–551
61 Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W,
Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J. Anatrozole versus
tamoxifen for the prevention of locoregional and contralateral breast cancer in
postmenopausal women with locally excised ductal carcinoma in situ (IBIS II DCIS): a double-
blind, randomised controlled trial. Lancet 2016;387:866–73
62 Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Withworth
PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K,
Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in
postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus
radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet
2016;387:849–56
63 Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Withworth
PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L,Sturtz K,
Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient reported outcomes with anastrozole
versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with
lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet 2016;387:857–65
64 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different
polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome
among 100 000 women in 123 randomised trials. Lancet. 2012;379[9814]:432–444.
65 Gluz O, Nitz U, Christgen M, Kates RE, et al. The WSG Phase III PlanB Trial: First Prospective
Outcome Data for the 21-gene Recurrence Score Assay and Concordance of Prognostic
Markers by Central and Local Pathology Assessment. J. Clin. Oncol [2016
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
66 Wolff AC, Hammond ME, Hicks DG, et al., Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline update. J Clin Oncol 2013, 313997–4013
67 Dowsett M, Sestak I, Buus R, et al., EndoPredict (EPclin) score for estimating residual distant
recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant
endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score
(RS). Cancer Res 2016;15;76; S3-01
68 Martin M, Brase JC, Calvo L, et al. Clinical validation of the EndoPredict test in node-positive,
chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Breast Cancer Res 2014;16 R38
69 Sparano JA, Gray RJ, Makower DF et al: Prospective Validation of a 21-Gene Expression Assay
in Breast Cancer. N Engl J Med 2015, 3732005–2014
70 Gluz O, Nitz U, Christgen M, Kates RE, et al. The WSG Phase III PlanB Trial: First Prospective
Outcome Data for the 21-gene Recurrence Score Assay and Concordance of Prognostic
Markers by Central and Local Pathology Assessment. J Clin Oncol. 2016 Feb 29. pii: JCO635383.
[Epub ahead of print]
71 Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early
average-to-high risk breast cancer patients.; SUCCESS Study Group. J Natl Cancer Inst. 2014
May 15;106 Bidard FC, Peeters DJ, Fehm Tet al. 2014. Clinical validity of circulating tumour
cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Lancet Oncol. 2014 Apr;15406–14
72 Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: Updates of national
surgical adjuvant breast and bowel project protocols b-18 and b-27. J Clin Oncol 2008;26:778–
785
73 Loibl S, Volz C, Mau C, et al: Response and prognosis after neoadjuvant chemotherapy in 1,051
patients with infiltrating lobular breast carcinoma. Breast cancer research and treatment
2014;144:153–162
74 Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F,
Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant
anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes:
Overall results from the gepartrio study. Breast cancer research and treatment 2010;124:133–
140
75 Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in
brca1-positive breast cancer patients. Breast cancer research and treatment 2014;147:401–40
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
76 von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-
negative and her2-positive early breast cancer (geparsixto; gbg 66]: A randomised phase 2
trial. The lancet oncology 2014;15:747–756
77 Ando M, Yamauchi H, Aogi K, et al., Randomized phase ii study of weekly paclitaxel with and
without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant
chemotherapy for stage ii/iiia breast cancer without her2 overexpression. Breast cancer
research and treatment 2014;145:401–409
78 Petrelli F, Coinu A, Borgonovo K, et al., The value of platinum agents as neoadjuvant
chemotherapy in triple-negative breast cancers: A systematic review and meta-analysis. Breast
cancer research and treatment 2014;144:223–232
79 Sikov WM, Berry DA, Perou CM, et al.: Impact of the addition of carboplatin and/or
bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin
and cyclophosphamide on pathologic complete response rates in stage ii to iii triple-negative
breast cancer: Calgb 40603 (alliance]. J Clin Oncol 2015;33:13–21
80 Untch M, Jackisch C, Schneeweiss A et al., Nab-paclitaxel versus solvent-based paclitaxel in
neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase
3 trial. Lancet Oncol. 2016 Mar;17345–56
81 von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J,
Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capecitabine
versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase
iii randomized gepartrio trial. J Natl Cancer Inst 2008;100:542–551
82 von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B,
Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kummel S, Paepke S, Schneeweiss A,
Untch M, Zahm DM, Mehta K, Loibl S: Response-guided neoadjuvant chemotherapy for breast
cancer. J Clin Oncol 2013;31:3623–3630
83 Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K: The value of tumor infiltrating lymphocytes (tils)
for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review
and meta-analysis. PloS one 2014;9:e115103
84 Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P,
Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F,
Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C:
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-
human epidermal growth factor receptor 2 (her2) therapy in primary her2-overexpressing
breast cancer. J Clin Oncol 2014;32:3212–3220
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
85 Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, Kuhn T, Kummel S, Rezai M,
Loibl S, von Minckwitz G: Impact of multifocal or multicentric disease on surgery and
locoregional, distant and overall survival of 6,134 breast cancer patients treated with
neoadjuvant chemotherapy. Ann Surg Oncol 2015;22:1118–1127
86 Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G,
Giard S. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast
cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective
multicentric study. J Clin Oncol. 2009 Feb 10;27726–32
87 Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG,
Taback B, Feliberti EC, Hunt KK. Identification and Resection of Clipped Node Decreases the
False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive
Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG
Z1071 (Alliance). Ann Surg. 2016;263:802-807
88 Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von
Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-
node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy
(SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14609–18
89 Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A,
Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L,
Patocskai E, Omeroglu A, Robidoux A. Sentinel Node Biopsy After Neoadjuvant Chemotherapy
in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J Clin Oncol. 2015;33258–
264
90 Losken A, Dugal CS, Styblo TM, Carlson GW: A meta-analysis comparing breast conservation
therapy alone to the oncoplastic technique. Annals of plastic surgery 2014;72:145–149
91 Berbers J, van Baardwijk A, Houben R, Heuts E, Smidt M, Keymeulen K, Bessems M, Tuinder S,
Boersma LJ: 'Reconstruction: Before or after postmastectomy radiotherapy?' A systematic
review of the literature. European journal of cancer 2014;50:2752–2762
92 Kelley BP, Ahmed R, Kidwell KM, Kozlow JH, Chung KC, Momoh AO: A systematic review of
morbidity associated with autologous breast reconstruction before and after exposure to
radiotherapy: Are current practices ideal? Ann Surg Oncol 2014;21:1732–1738
93 Wang XL, Liu LB, Song FM, Wang QY: Meta-analysis of the safety and factors contributing to
complications of ms-tram, diep, and siea flaps for breast reconstruction. Aesthetic plastic
surgery 2014;38:681–691
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
94 Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD,
Sautter-Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R; Breast Cancer Expert Panel of the
German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2014 Aug;190705–14
95 Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Fussl C, Haase W, Harms
W, Piroth MD, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society
of Radiation Oncology (DEGRO). Strahlenther Onkol. 2014 Apr;190342–51
96 Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P,
Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR;
START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of
radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results
of two randomised controlled trials. Lancet Oncol. 2013 Oct;141086–94
97 Coates AS1, Winer EP2, Goldhirsch A3, Gelber RD4, Gnant M5, Piccart-Gebhart M6,
Thürlimann B7, Senn HJ8; Panel Members. Tailoring therapies-improving the management of
early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2015. Ann Oncol. 2015 Aug;261533–46
98 Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:A Brief Summary of the Consensus
Discussion. Breast Care (Basel). 2015 Apr;10124–30; Smith BD, Bentzen SM, Correa CR, Hahn
CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A,
Taghian AG, Vicini FA, White JR, Haffty BG. Fractionation for whole breast irradiation: an
American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol
Biol Phys. 2011 Sep 1;8159–68
99 Harris JR. Critical Decision-Making in Radiation Therapy for Breast Cancer. Presentation at the
San Antonio Breast Cancer Symposium 2015. Cancer Res February 15, 2016 76:PL1–01
100 Yarnold J. Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-
genomic issues. Breast 2015;24(Suppl 1): PG 10.01
101 Whelan T. Tailoring or omitting radiotherapy in early breast cancer. Cancer Res February 15,
2016 76:ES6–2
102 Bartelink H, Maingon P, Poortmans P, et al.; European Organisation for Research and
Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation
with or without a boost for patients treated with breast-conserving surgery for early breast
cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan;1647–56
103 Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL,
Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J
Clin Oncol. 2013 Jul 1;312382–7
104 EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C,
Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-
year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22
randomised trials. Lancet. 2014 Jun 21;383[9935]:2127–35
105 Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local
recurrence risk is not associated with large survival reduction after postmastectomy
radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol.
2009 Jan;9074–9
106 Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer
patients with T1-T2 tumours and one to three positive axillary nodes at high postmastectomy
locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Apr
1;611337–47
107 Shen H, Zhao L, Wang L, Liu X, Liu X, Liu J, Niu F, Lv S, Niu Y. Postmastectomy radiotherapy
benefit in Chinese breast cancer patients with T1-T2 tumour and 1–3 positive axillary lymph
nodes by molecular subtypes: an analysis of 1369 cases. Tumour Biol. 2015 Dec 2
108 Poortmans PM, Collette S, Kirkove C, et al.; EORTC Radiation Oncology and Breast Cancer
Groups. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J
Med. 2015 Jul 23;373317–27
109 Whelan TJ, Olivotto IA, Parulekar WR, et al.; MA.20 Study Investigators. Regional Nodal
Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373307–16
110 Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A Population-Based Cohort Study on the
Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol.
2016 Feb 1;34314–20
111 Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant
radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized
trials- an update. Radiat Oncol. 2015 Dec 21;10:258
112 Gray RG, Handley K, Bowden SJ: Attom: Long-term effects of continuing adjuvant tamoxifen to
10 years versus stopping at 5 years in 6,953 women with early breast cancer: ASCO, 2013
113 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer
MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
tamoxifen therapy for early-stage breast cancer. The New England journal of medicine
2003;349:1793–1802
114 Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein
HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Jr., Pinotti G, Puglisi F,
Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A,
Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA,
Text, Investigators S, International Breast Cancer Study G: Adjuvant exemestane with ovarian
suppression in premenopausal breast cancer. The New England journal of medicine
2014;371:107–118
115 Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein
HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Jr., Pinotti G, Puglisi F,
Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A,
Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA,
Text, Investigators S, International Breast Cancer Study G: Adjuvant exemestane with ovarian
suppression in premenopausal breast cancer. The New England journal of medicine
2014;371:107–118
116 Jacobs SA, Wilson JW, Bandos H, al. e: NSABP B-36:Randomized phase III trial comparing 6
cycles of 5-FU, epirubicin, and cyclophosphamide (FEC) to 4 cycles of ac in node-negative
breast cancer: SABCS. San Antonio, 2014
117 Sparano JA, Zhao F, Martino S, Ligibel J, Saphner T, Wolff AC, Sledge GW, Perez EA, Wood WC,
Davidson NE: Ten year update of e1199:Phase iii study of doxorubicin-cyclophosphamide
followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary
node-positive or high-risk node-negative breast cancer: SABCS. San Antonio, 2014
118 Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus cmf as adjuvant chemotherapy
for older women with early breast cancer: Final results of the randomized phase iii elda trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2015;26:675–682
119 Shulman LN, Berry DA, Cirrincione CT, et al., Comparison of doxorubicin and cyclophosphamide
versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3
positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311-2317
120 Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al., 2 years versus 1 year of adjuvant
trastuzumab for her2-positive breast cancer (hera): An open-label, randomised controlled trial.
Lancet 2013;382:1021–1028
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
121 Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for
patients with her2-positive early breast cancer (phare): A randomised phase 3 trial. The lancet
oncology 2013;14:741–748
122 Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative,
her2-positive breast cancer. The New England journal of medicine 2015;372:134–141
123 Piccart-Gebhart M, Holmes AP, Baselga J, al. e: First results from the phase iii altto trial (big
02–06; ncctg 063d) comparing one year of anti-her2 therapy with lapatinib alone (l),
trastuzumab alone (t), their sequence (t→l) or their combination (l + t) in the adjuvant
treatment of her2-positive early breast cancer (ebc): ASCO, 2014
124 Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz B,
Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E: Tibolone
increases bone mineral density but also relapse in breast cancer survivors: Liberate trial bone
substudy. Breast cancer research : BCR 2012;14:R13
125 Buchholz S, Mogele M, Lintermans A, Bellen G, Prasauskas V, Ortmann O, Grob P, Neven P,
Donders G: Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated
breast cancer. Climacteric : the journal of the International Menopause Society 2015;18:252–
259
126 Loibl S, Lintermans A, Dieudonne AS, Neven P: Management of menopausal symptoms in
breast cancer patients. Maturitas 2011;68:148–154
127 Roberts H: Safety of herbal medicinal products in women with breast cancer. Maturitas
2010;66:363–369
128 Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla
RL, Steen PD, Vuky J, Barton DL: A phase iii, randomized, placebo-controlled, double-blind trial
of flaxseed for the treatment of hot flashes: North central cancer treatment group n08c7.
Menopause 2012;19:48–53
129 Leach MJ, Moore V: Black cohosh (cimicifuga spp.) for menopausal symptoms. Cochrane
Database Syst Rev 2012;9:Cd007244
130 Caraci F, Crupi R, Drago F, Spina E: Metabolic drug interactions between antidepressants and
anticancer drugs: Focus on selective serotonin reuptake inhibitors and hypericum extract.
Current drug metabolism 2011;12:570–577
131 Kim MS, Lim HJ, Yang HJ, Lee MS, Shin BC, Ernst E: Ginseng for managing menopause
symptoms: A systematic review of randomized clinical trials. Journal of ginseng research
2013;37:30–36
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
132 Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, Kennedy D, Cooley K,
Wong R, Sagar S, Sabri E, Fergusson D. Soy, red clover, and isoflavones and breast cancer: a
systematic review. PLoS One. 2013 Nov 28;8e81968.
133 Ghazanfarpour M, Sadeghi R, Latifnejad Roudsari R, Mirzaii Najmabadi K, Mousavi Bazaz M,
Abdolahian S, Khadivzadeh T. Effects of red clover on hot flash and circulating hormone
concentrations in menopausal women: a systematic review and meta-analysis. Avicenna J
Phytomed. 2015 Nov-Dec;5498–511.
134 Mann E: Cognitive behavioural treatment for women who have menopausal symptoms after
breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012
Mar;13309–18.
135 Buffart LM: Physical and psychosocial benefits of yoga in cancer patients and survivors, a
systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012 Nov
27;12:559
136 Cramer H: Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC
Complement Altern Med. 2014 Sep 2;14:328
137 Moore HC, Unger JM, Phillips KA, et al., Goserelin for ovarian protection during breast-cancer
adjuvant chemotherapy. The New England journal of medicine 2015;372:923–932
138 Committee opinion no. 618: Ovarian reserve testing. Obstetrics and gynecology 2015;125:268–
273
139 Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S: Caring for the breast cancer
survivor's health and well-being. World journal of clinical oncology 2014;5:693–704
140 Hatzichristou D, Rosen RC, Denogatis LR, Low WY, Sadovsky R, Symonds T. Recommendations
for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010:7:337–
348
141 Bao PP, Lu W, Cui Y, Zheng Y, Gu K, Chen Z, Zheng W, Shu XO: Ginseng and ganoderma lucidum
use after breast cancer diagnosis and quality of life: A report from the shanghai breast cancer
survival study. PloS one 2012;7:e39343
142 Ryan JL, Heckler CE, Ling M, Katz A, Williams JP, Pentland AP, Morrow GR: Curcumin for
radiation dermatitis: A randomized, double-blind, placebo-controlled clinical trial of thirty
breast cancer patients. Radiation research 2013;180:34–43
143 Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, Nechuta SJ, Poole EM, Shu
XO, Chen WY: Lifetime cigarette smoking and breast cancer prognosis in the after breast
cancer pooling project. J Natl Cancer Inst 2014;106:djt359
Breast Care
DOI: 10.1159/000446941 © 2016 S. Karger GmbH, Freiburg www.karger.com/brc
Supplementary Material
144 Xing MY, Xu SZ, Shen P: Effect of low-fat diet on breast cancer survival: A meta-analysis. Asian
Pacific journal of cancer prevention : APJCP 2014;15:1141–1144
145 Kroenke CH, Kwan ML, Sweeney C, Castillo A, Caan BJ: High- and low-fat dairy intake,
recurrence, and mortality after breast cancer diagnosis. J Natl Cancer Inst 2013;105:616–623
146 Poole EM, Shu X, Caan BJ, Flatt SW, Holmes MD, Lu W, Kwan ML, Nechuta SJ, Pierce JP, Chen
WY: Postdiagnosis supplement use and breast cancer prognosis in the after breast cancer
pooling project. Breast cancer research and treatment 2013;139:529–537
147 Harris HR, Orsini N, Wolk A: Vitamin c and survival among women with breast cancer: A meta-
analysis. European journal of cancer 2014;50:1223–1231
148 Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF: Meta-analysis of vitamin d sufficiency for
improving survival of patients with breast cancer. Anticancer Res 2014;34:1163–1166
149 Greenlee H, Kwan ML, Kushi LH, Song J, Castillo A, Weltzien E, Quesenberry CP, Jr., Caan BJ:
Antioxidant supplement use after breast cancer diagnosis and mortality in the life after cancer
epidemiology (lace) cohort. Cancer 2012;118:2048–2058
150 Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, Kennedy D, Cooley K,
Wong R, Sagar S, Sabri E, Fergusson D: Soy, red clover, and isoflavones and breast cancer: A
systematic review. PloS one 2013;8:e81968
151 Fritz H, Seely D, McGowan J, Skidmore B, Fernandes R, Kennedy DA, Cooley K, Wong R, Sagar S,
Balneaves LG, Fergusson D: Black cohosh and breast cancer: A systematic review. Integrative
cancer therapies 2014;13:12–29
152 Towler P, Molassiotis A, Brearley SG: What is the evidence for the use of acupuncture as an
intervention for symptom management in cancer supportive and palliative care: An integrative
overview of reviews. Supportive care in cancer : official journal of the Multinational
Association of Supportive Care in Cancer 2013;21:2913–2923
153 Cramer H, Lauche R, Paul A, Dobos G: Mindfulness-based stress reduction for breast cancer-a
systematic review and meta-analysis. Current oncology (Toronto, Ont) 2012;19:e343–352